Supplementary Table I. Adverse events during conventional (sDMARDs) and biologic treatment (bDMARDs) in rheumatoid arthritis patients.

Adverse events during treatment	sDMARDs (n=609)	bDMARDs (n=519)
Infections	69 (11.3%)	188 (36.2%)
Pulmonary	29	92
Urinary	16	40
Tuberculosis	2	5
Herpes viruses	9	10
Skin-mucous membrane	7	19
Bones-joints	1	8
Viral hepatitis	2	2
Meningitis	1	1
Peritonitis	0	1
Leismaniasis	1	0
Sepsis	0	2
Other	1	8
Liver function tests	181 (29.7%)	62 (11.9%)
Cardiovascular events	40 (6.6%)	24 (4.6%)
Skin-mucous membrane	81 (13.3%)	42 (8.1%)
Psoriasiform rash	1	15
Keratoderma blennorrhagicum	1	5
Purpura-vasculitis	2	2
Other	77	20
Allergy	19 (3.1%)	81 (15.6%)
Dyslipidaemia	6 (1.0%)	34 (6.5%)
Gastrenterologic events	56 (9.2%)	14 (2.7%)
Blood disorders	71 (11.6%)	18 (3.5%)
Renal disorders	30 (4.9%)	3 (0.6%)
Pulmonary fibrosis	8 (1.3%)	0
Drug-induced SLE	0	5 (0.9%)
Peripheral neuropathy-polyneuritis	0	3 (0.6%)
Other adverse events	48 (7.9%)	45 (8.7%)

sDMARDs: synthetic disease-modifying anti-rheumatic drugs; bDMARDs: biologic disease-modifying anti-rheumatic drugs.